Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology into new therapeutics for retinal disease and cancer. Its lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD by targeting inflammation and angiogenesis together. The company completed a Phase 1 clinical trial in wet AMD and has completed enrollment in EMERGE, a Phase 2a study in newly diagnosed AMD patients. Iconic is also investigating the ICON family of proteins in cancer, has initiated a research program in solid tumors, and plans to begin clinical trials in ocular melanoma as its first oncology indication. Proceeds from the Series C financing will be used to advance ICON-1 development in retinal diseases and to begin the ocular melanoma program. The company is based in South San Francisco, Calif. Iconic Therapeutics is a clinical‑stage biotech focused on developing treatments for serious eye disorders, principally age‑related macular degeneration. Its lead program is hI‑con1, a recombinant human chimeric protein licensed from Yale that binds tissue factor, a promoter of inflammation and angiogenesis. When hI‑con1 binds tissue factor it harnesses the immune system to selectively destroy pathologic neovascular blood vessels and may also reduce VEGF levels. The company has completed a Phase 1 clinical trial in the U.S. and is planning an international Phase 2 study. Iconic is based in Atlanta, GA and South San Francisco, CA, and is led by Co‑Founder and President Kirk Dornbush alongside newly appointed CEO William Greene. The company completed a $20M Series B‑1 equity financing.

Total raised

$30M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2016